Cargando…

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer

The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Byeongju, Lee, Jeeyeon, Jung, Jin Hyang, Kim, Wan Wook, Keum, Heejung, Park, Ho Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470803/ https://www.ncbi.nlm.nih.gov/pubmed/37653831 http://dx.doi.org/10.1097/MD.0000000000034772

Ejemplares similares

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers
por: Lee, Seokwon, et al.
Publicado: (2021)

p-STAT3 expression in breast cancer correlates negatively with tumor size and HER2 status
por: Wang, Yan, et al.
Publicado: (2021)

High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
por: Liu, Yu-Lin, et al.
Publicado: (2015)

Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis
por: Chen, Xuan, et al.
Publicado: (2023)

MicroRNA-496 inhibits triple negative breast cancer cell proliferation by targeting Del-1
por: Lee, Soo Jung, et al.
Publicado: (2021)

Acellular dermal matrix combined with oxidized regenerated cellulose for partial breast reconstruction: Two case reports
por: Lee, Jeeyeon, et al.
Publicado: (2020)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis
por: Wang, Hong-Bo, et al.
Publicado: (2017)

Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report
por: Sun, Maoben, et al.
Publicado: (2023)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Comparison between ultrasound-guided aspiration performed using an intravenous cannula or a conventional needle in patients with peri-prosthetic seroma
por: Lee, Jeeyeon, et al.
Publicado: (2019)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Luminal B breast tumors are not HER2 positive – authors' response
por: Tamimi, Rulla M, et al.
Publicado: (2008)

Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer
por: Lesniak, David, et al.
Publicado: (2013)

6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer
por: Wang, Di, et al.
Publicado: (2016)

PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER
por: Rajc, Jasmina, et al.
Publicado: (2018)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
por: Lee, In Hee, et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies
por: Zhang, Qingyu, et al.
Publicado: (2016)

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
por: Park, Soon Young, et al.
Publicado: (2023)

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer
por: Park, Chansub, et al.
Publicado: (2016)

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
por: Alvarez-Lopez, I., et al.
Publicado: (2020)

A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
por: Yang, Xue, et al.
Publicado: (2023)

Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report
por: Jung, Sung Ui, et al.
Publicado: (2021)

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
por: Utsumi, Toshiaki, et al.
Publicado: (2021)

Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
por: Lee, Jeeyeon, et al.
Publicado: (2022)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer
por: Sim, Sung Hoon, et al.
Publicado: (2017)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

High prevalence of the MLH1 V384D germline mutation in patients with HER2-positive luminal B breast cancer
por: Lee, Seung Eun, et al.
Publicado: (2019)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study
por: Shokouh, Taghipour Zahir, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6o66i6porfnh7c87cngv26srib